|
MeVis Medical Solutions AG / Key word(s): Change in Forecast MeVis Medical Solutions AG: Adjusting forecast for the current fiscal year 31-Jul-2023 / 16:27 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Bremen, July 31, 2023 – MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading provider of medical imaging software, is adjusting its annual forecast for the current fiscal year based on the preliminary business figures for the first ten months. In light of a challenging macroeconomic environment with accelerating inflation and the ongoing war in Ukraine, MeVis Medical Solutions AG sees its revenue performance more cautious than before due to current project developments and subdued expectations in new projects. For fiscal year 2022/2023 (October 1, 2022 to September 30, 2023), revenues are now expected to decline to between € 17.0 million and € 17.5 million (previous forecast: stable revenues of € 18.0 million to € 18.5 million). EBIT (earnings before interest and taxes) is expected to be in a range of € 3.5 million to € 4.0 million in fiscal 2022/2023 in view of the changed assumptions (previous forecast: decline to € 4.5 million to € 5.0 million). In addition, earnings have been strongly impacted by the development of the US dollar/euro exchange rate since the beginning of the fiscal year. Contact: Kirchhoff, Marcus / CEO End of Inside Information 31-Jul-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Where are the adcomms? FDA has scheduled no drug or biologic meetings for 2024 so far
The FDA’s advisory committees of outside experts typically review controversial drug approval decisions at meetings scheduled months in advance. But the agency’s adcomm calendar for
January 4, 2024